Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ian N, Foltz"'
Autor:
Neungseon Seo, Xiaoyan Guan, Tian Wang, Hyo S. Helen Chung, Mats Wikström, Rupa Padaki, Kevin Kalenian, Scott Kuhns, Kelli Matthies, Jill Crouse-Zeineddini, Helen Y. Wong, Michael Ng, Ian N. Foltz, Shawn Cao, Jennifer Liu
Publikováno v:
Ophthalmology and Therapy, Vol 13, Iss 5, Pp 1303-1320 (2024)
Abstract Introduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders. This study was designed to provide a comparative analytical assessment of the stru
Externí odkaz:
https://doaj.org/article/f2288437a8274d48b45398da06a6f337
Autor:
William C. Fanslow, John S. Hill, Qing Chen, Steven L. Vonderfecht, Brian Twomey, Taruna Arora, David Meininger, Esther S. Trueblood, Ian N. Foltz, Hua Liu, Wesley S. Chang, Sophia Siu, Carl J. Kozlosky, Kevin J. Hamblett
Supplementary Figure S2. Cell Growth inhibition in A431 cells (wild-type EGFR overexpressing cells)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::157c052f73fd90111b36159268b5cbaf
https://doi.org/10.1158/1535-7163.22502325
https://doi.org/10.1158/1535-7163.22502325
Autor:
William C. Fanslow, John S. Hill, Qing Chen, Steven L. Vonderfecht, Brian Twomey, Taruna Arora, David Meininger, Esther S. Trueblood, Ian N. Foltz, Hua Liu, Wesley S. Chang, Sophia Siu, Carl J. Kozlosky, Kevin J. Hamblett
Supplementary Figure Legends and Supplementary Table. Supplementary Table. EGFRvIII receptors/cell quantification of U251vIII and D317
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03bcc3ebe52bd2ceb4e27bea2e01fbbc
https://doi.org/10.1158/1535-7163.22502331
https://doi.org/10.1158/1535-7163.22502331
Autor:
Simon T. Barry, Vahe Bedian, David C. Blakey, Hazel M. Weir, Neil R. Smith, Dawn Baker, Li Peng, Melissa Damschroder, Song Cho, Philip Petteruti, Jane Kendrew, Cath Eberlein, Kathy Manchulenko, Brandon C. Clavette, Ian N. Foltz, Margaret Veldman-Jones, Sarah Ross, David W. Jenkins
PDF file - 153K, Figure to support screening for antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82f789567bdbe38aa8242ddaae517a98
https://doi.org/10.1158/1535-7163.22497729.v1
https://doi.org/10.1158/1535-7163.22497729.v1
Autor:
Simon T. Barry, Vahe Bedian, David C. Blakey, Hazel M. Weir, Neil R. Smith, Dawn Baker, Li Peng, Melissa Damschroder, Song Cho, Philip Petteruti, Jane Kendrew, Cath Eberlein, Kathy Manchulenko, Brandon C. Clavette, Ian N. Foltz, Margaret Veldman-Jones, Sarah Ross, David W. Jenkins
PDF file - 98K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f07ae0e482808c3b8eacc87796d9ded
https://doi.org/10.1158/1535-7163.22497726.v1
https://doi.org/10.1158/1535-7163.22497726.v1
Autor:
Simon T. Barry, Vahe Bedian, David C. Blakey, Hazel M. Weir, Neil R. Smith, Dawn Baker, Li Peng, Melissa Damschroder, Song Cho, Philip Petteruti, Jane Kendrew, Cath Eberlein, Kathy Manchulenko, Brandon C. Clavette, Ian N. Foltz, Margaret Veldman-Jones, Sarah Ross, David W. Jenkins
The Notch signaling pathway has been implicated in cell fate determination and differentiation in many tissues. Accumulating evidence points toward a pivotal role in blood vessel formation, and the importance of the Delta-like ligand (Dll) 4-Notch1 l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58d542fb2b425861aad9c75220d50b1b
https://doi.org/10.1158/1535-7163.c.6535701.v1
https://doi.org/10.1158/1535-7163.c.6535701.v1
Autor:
Agnieszka Kielczewska, Igor D'Angelo, Maria Sheena Amador, Tina Wang, Athena Sudom, Xiaoshan Min, Palaniswami Rathanaswami, Craig Pigott, Ian N. Foltz
Publikováno v:
The Journal of biological chemistry. 298(2)
Therapeutic antibody development requires discovery of an antibody molecule with desired specificities and drug-like properties. For toxicological studies, a therapeutic antibody must bind the ortholog antigen with a similar affinity to the human tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::271ee90fc2b9177d1e7f2e6b08b4abdf
https://pubmed.ncbi.nlm.nih.gov/34973336
https://pubmed.ncbi.nlm.nih.gov/34973336
Autor:
Qingwen, Cheng, Jean, Danao, Santosh, Talreja, Paul, Wen, Jun, Yin, Ning, Sun, Chi-Ming, Li, Danny, Chui, David, Tran, Samir, Koirala, Hang, Chen, Ian N, Foltz, Songli, Wang, Shilpa, Sambashivan
Publikováno v:
The Journal of biological chemistry. 293(32)
Triggering receptor expressed on myeloid cells 2 (TREM2) is an orphan immune receptor expressed on cells of myeloid lineage such as macrophages and microglia. The rare variant R47H TREM2 is associated with an increased risk for Alzheimer's disease, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3fb6d75683f871cfc59a96af475b98f0
https://pubmed.ncbi.nlm.nih.gov/29599291
https://pubmed.ncbi.nlm.nih.gov/29599291
Autor:
Paula J. Kaplan-Lefko, Jonathan D. Graves, Stephen J. Zoog, Yang Pan, Jason Wall, Daniel G. Branstetter, Jodi Moriguchi, Angela Coxon, Justin N. Huard, Ren Xu, Matthew L. Peach, Gloria Juan, Stephen Kaufman, Qing Chen, Allison Bianchi, Jennifer J. Kordich, Mark Ma, Ian N. Foltz, Brian C. Gliniak
Publikováno v:
Cancer biologytherapy. 9(8)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to death receptors 4 and 5 (DR4, DR5) to transduce apoptotic signals. Conatumumab (AMG 655) is an investigational, fully human monoclonal agonist antibody (IgG(1)) to human DR5, wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a3ef007c8117f27881243c57ccdbfdc
https://pubmed.ncbi.nlm.nih.gov/20150762
https://pubmed.ncbi.nlm.nih.gov/20150762